KNL1 and neoplasm: The results of this study indicate that upregulation of KNL1 expression may be adverse to the antitumor immune response of the body, and it is significantly positively correlated with the immunotherapy target CD47, suggesting that KNL1 may be a potential immunotherapy target for tumor immunotherapy.